Short answer: No, there isn’t a generic version of Tremfya (tildrakizumab) on the market as of now.
---
Why that’s the case
| What it is | Why generics aren’t available yet |
|------------|-----------------------------------|
| Tremfya is a biologic drug (a human monoclonal antibody) used primarily for moderate‑to‑severe plaque psoriasis. | Biologics are built in living cells, not chemically synthesized. They’re too complex to copy exactly, so the regulatory pathway is different. |
| It’s produced by Amgen (and its marketing partner, Sanofi). | The original manufacturer holds an exclusive biologic license that lasts many years (typically 12–15 years). |
| The drug’s name, “tildrakizumab,” is protected under U.S. patent and brand‑name law. | Generic approval for biologics is actually “biosimilar” approval. It requires showing that the new product is highly similar in safety, purity, potency, and efficacy to the reference product. |
---
Current regulatory status (U.S. & EU)
| Region | Status |
|--------|--------|
| United States | The FDA has not approved a biosimilar to tildrakizumab. No generic equivalent is available. |
| European Union | The EMA has not yet approved any biosimilar for tildrakizumab either. |
| Other markets | Some countries may have local biosimilars under review, but they’re not yet in widespread use. |
---
What you might want to consider
| Option | What it means |
|--------|---------------|
| Other biologics | Drugs like Cosentyx (secukinumab) or Stelara (ustekinumab) are approved for psoriasis and have their own brand and, in some cases, biosimilar options. |
| Non‑biologic systemic agents | Oral options such as methotrexate or cyclosporine may be alternatives, depending on disease severity and patient factors. |
| Clinical trials | Patients can sometimes enroll in trials testing new or cheaper formulations, including biosimilars, if they’re available. |
---
How to find out if a biosimilar is coming
1. FDA’s “Approved Biologics” page – updates when a new biosimilar receives approval.
2. EMA’s “Biologics” portal – similar listings for European approvals.
3. Pharmacy/Health‑Insurance portals – they often list newly available generics or biosimilars and may adjust coverage accordingly.
---
Bottom line
If you’re looking for a lower‑cost alternative to Tremfya, the most realistic route right now is to talk to your prescriber about other approved biologics or systemic therapies. A biosimilar version of tildrakizumab might appear in the future, but it isn’t on the market yet.
Always consult your healthcare provider for decisions about medication changes.